Verrica Pharmaceuticals
verrica.com
Actively hiring
Dermatology
Health Care
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
News
Verrica Pharmaceuticals stock trades at USD 4.10
Verrica Pharmaceuticals stock traded at USD 4.10 on September 22, 2026, down 2.92 percent over 24 hours. Quarterly revenue reached USD 12.70 million.
Read more
Report
Verrica Pharmaceuticals stock holds steady as investors watch latest clinical and earnings signals
Verrica Pharmaceuticals stock trades on Nasdaq in a tight range as of September 21, 2026, with investors focusing on recent revenue trends and cash burn. The company's latest quarterly figures frame the risk-reward in dermatology drug development.
Read more
Report
Verrica Pharmaceuticals to Present YCANTH and VP-315 Data at Two Upcoming Dermatology Conferences
- Post-hoc analysis shows YCANTH drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration -WEST CH...
Read more
Report
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (
Read more
Report
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (
Read more
Report
Verrica Pharmaceuticals provides update on new commerical strategy for YCANTH
Verrica Pharmaceuticals (VRCA) announced a business and operational update outlining the significant progress being made with respect to the new commercial strategy for YCANTH, Verrica's lead product for the treatment of molluscum contagiosum. "Over the l
Read more
Report
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders seem bullish, own 40% and have been buying more recently
Every investor in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) should be aware of the most powerful shareholder groups. With 40% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock
Read more
Report
Tech stack
Technologies named in job postings at Verrica Pharmaceuticals over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Practices & domains
IAM
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
28/100
Slowing
Open positions
6
0 opened / 0 closed in 30 days
ATS activity
Every ~3 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Field & Service
100%
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
1
Busiest office
Cleveland
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cleveland
United States
1 open roles 50-200 est. staff
hires for Marketing
West
United States
Regional office
West Chester, PA 19380
West Chester, PA 19380